Chemomab Therapeutics (CMMB, $3.68) shares jump, on Phase 2a trial results for CM-101
Chemomab Therapeutics Ltd shares jumped on Tuesday, after it reported topline results from its Phase 2a trial assessing CM-101 in non-alcoholic steatohepatitis (NASH) patients.
While the trial met its primary endpoint of safety and tolerability, CM-101 achieved reductions in secondary endpoints that include liver fibrosis biomarkers and physiologic assessments measured at baseline and week 20.
Patients treated with CM-101 showed more significant improvements than the group that was given placebo treatment, in several liver fibrosis-related biomarkers.
Around 60% of CM-101-treated patients responded in at least three biomarkers at week 20, while no patients did in the placebo group. A higher percentage of patients in the CM-101-treated group showed improvement in a physiologic measure of liver stiffness compared to the placebo group.
CMMB in +9.29% Uptrend, rising for three consecutive days on March 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CMMB advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on February 27, 2026. You may want to consider a long position or call options on CMMB as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
CMMB moved above its 50-day moving average on February 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CMMB crossed bullishly above the 50-day moving average on March 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMMB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CMMB broke above its upper Bollinger Band on February 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CMMB entered a downward trend on February 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.080) is normal, around the industry mean (30.245). P/E Ratio (0.000) is within average values for comparable stocks, (40.902). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.820). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (315.809).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CMMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services
Industry Biotechnology
Advertisement